GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Short Interest

Gensight Biologics (XPAR:SIGHT) Short Interest


View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Gensight Biologics's Short Interest

For the Biotechnology subindustry, Gensight Biologics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gensight Biologics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's Short Interest distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's Short Interest falls into.


Gensight Biologics (XPAR:SIGHT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Short Interest
Comparable Companies
XPAR:ALDVI XPAR:ALCOX XPAR:PHXM XPAR:POXEL XPAR:ALVIO XPAR:GNRO XPAR:FALG XPAR:ALHYG XPAR:ALGEN XPAR:ALNFL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
GSGTF:USA G49N:Germany
Address
74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Website
https://www.gensight-biologics.com
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines